PUMA BIOTECHNOLOGY, INC.

PUMA BIOTECHNOLOGY, INC. insiders are currently net sellers of PBYI stock, showing bearish sentiment over the past 90 days. Total sales of $173.2M outpace purchases of $54.7M, creating a net outflow of $118.6M.

PUMA BIOTECHNOLOGY, INC. has 26 active insiders who have filed SEC Form 4 transactions in the past 90 days. Capital Partners Gp, L.l.c. Adage (Executive) leads with 20 transactions totaling $113.0M. Capital Partners, L.p. Adage (Executive) follows with 23 transactions worth $55.5M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. PUMA BIOTECHNOLOGY, INC.'s current score of 24/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Feb 18, 2026, when F. Nougues Maximo (Chief Financial Officer) acquired 66,541 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, PBYI insider trading sentiment is currently bearish with an Alignment Score of 24/100. The negative net flow of $118.6M shows more selling than buying. However, 26% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like PUMA BIOTECHNOLOGY, INC.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At PBYI, we track all Form 4 filings—currently showing 411 transactions from 26 insiders over 90 days.

A 10b5-1 plan allows PUMA BIOTECHNOLOGY, INC. executives to pre-schedule stock sales when they don't possess material non-public information. At PBYI, approximately 26% of recent transactions are 10b5-1 trades. The remaining 74% are discretionary trades, which may carry more informational value.

You can monitor PUMA BIOTECHNOLOGY, INC. (PBYI) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 26 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. PUMA BIOTECHNOLOGY, INC.'s current score of 24/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $54.7M in purchases versus $173.2M in sales over 90 days, resulting in a net flow of -$118.6M.

SEC Form 4 filings are mandatory reports that PUMA BIOTECHNOLOGY, INC. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At PBYI, the most common type is "S" with 28 occurrences. The most recent Form 4 was filed on Feb 18, 2026 by F. Nougues Maximo.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At PUMA BIOTECHNOLOGY, INC., approximately 26% of recent transactions are executed under 10b5-1 plans, while 74% appear to be discretionary trades. This mix provides a balanced picture—some planned, others reflecting real-time decisions.